Shares of Equillium (NASDAQ: EQ) soared in morning trading on Tuesday after the clinical-stage biotechnology company announced positive interim clinical results from the Type B portion of its EQUALISE study.
The study evaluated itolizumab, a first-in-class anti-CD6 monoclonal antibody used in the treatment of Lupus Nephritis.
The company stated that at the end of the study, 83% of patients achieved a complete or partial clinical response, with 67% reaching a greater than 80% reduction in urine protein creatinine ratio (UPCR). UPCR detects the presence of proteins in the urine as lupus nephritis affects the kidneys.
Bruce Steel, CEO of Equillium stated, “The interim data adds to our conviction in the clinical activity of itolizumab and the potential to be an impactful therapy for patients with lupus nephritis. We look forward to continuing to enroll patients in the Type B portion of the EQUALISE study and anticipate sharing topline data in mid-2023. “